Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,553 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05862168RecruitingPhase 2
Tislelizumab with chemotherapy before surgery for oral cancer
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
HangzhouAges 18–75 - NCT05984485RecruitingPhase 3
Surgery vs chemo before surgery for low-risk rectal cancer
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05450029RecruitingPhase 2
Adding immunotherapy to chemo-radiation for rectal cancer
This Phase 2 trial studies whether adding sintilimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with locally advanced rectal cancer. It’s aimed at tumors with certain immune “signature” scores and specific cancer stage features.
Guangzhou, GuangdongAges 18–75 - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT03964753RecruitingPhase 2
Chemo before surgery for middle-lower esophageal cancer
This trial tests a chemotherapy combination (nab-paclitaxel plus cisplatin) given before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to shrink the tumor and improve outcomes by treating cancer earlier while it’s still in one region.
Shijiazhuang, HebeiAges 18–75 - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT05624099RecruitingPhase 2
Camrelizumab plus chemoradiotherapy for advanced esophageal cancer
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
FuzhouAges 18–75 - NCT06120387Recruiting
Radiation after kidney-sparing surgery for high-risk ureteral cancer
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
BeijingAges 18 years+ - NCT06170294RecruitingPhase 1
MAGE-A4 TCR-T therapy for advanced solid tumors
This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT04134780Recruiting
Ultrasound tests to spot early breast cancer treatment response
This study uses special ultrasound imaging (and may use MRI results) to look for early signs of how locally advanced breast cancer responds to chemotherapy, with or without radiation. If the imaging changes early, it could help doctors adjust treatment sooner.
Houston, TexasAges 18 years+ - NCT05833594Recruiting
Immunonutrition plus chemoradiation for unresectable esophageal cancer
This trial studies whether adding an “immunonutrition” nutrition plan to standard chemoradiation can improve outcomes for people with locally advanced, unresectable esophageal squamous cell cancer. It may help the treatment work better by supporting the immune system during therapy.
HefeiAges 18–85 - NCT05446545Recruiting
Blood and tissue tests to monitor ovarian cancer using tumor DNA
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05140746Recruiting
Predicting how well chemotherapy works before stomach surgery
This study looks for ways to predict whether neoadjuvant chemotherapy (chemo given before surgery) will work well in people with locally advanced stomach cancer. It may help doctors choose the best treatment plan sooner based on your test results.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07865793RecruitingPhase 2
Lattice radiation with immunotherapy for advanced tumors
This trial tests a new way to give radiation called lattice therapy together with immunotherapy drugs that help your immune system fight cancer. It is for people with advanced solid tumors that have grown or spread, with at least one large tumor that can be measured.
Shenzhen, GuangdongAges 18–70 - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06220617Recruiting
Early detection of colorectal cancer using blood tests
This study is looking for people newly diagnosed with colorectal cancer or advanced adenoma to help find better ways to detect the disease early using advanced lab tests on blood samples.
Hangzhou, ZhejiangAges 18 years+ - NCT06240689RecruitingPhase 2
Immune maintenance therapy after chemoradiotherapy for head and neck cancer
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
Hangzhou, ZhejiangAges 18–75 - NCT06251388RecruitingPhase 2
Chemoradiation plus Cadonilimab for advanced cervical cancer
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT06254690RecruitingPhase 2
Pyrotinib dosing study for HER2-positive advanced breast cancer
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Nanjing, JiangsuAges 18–70 - NCT06151262RecruitingPhase 2
Trilaciclib plus mFOLFIRINOX for advanced pancreatic cancer
This trial tests a new drug, trilaciclib, combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if adding trilaciclib can help reduce side effects and improve how well the treatment works.
Nanjing, JiangsuAges 18–75 - NCT01935778RecruitingPhase 3
Extra chemo after stomach cancer surgery: compare two drug plans
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
SeoulAges 20–75 - NCT07869823RecruitingEarly Phase 1
Skin cancer treatment for head and neck
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
St Louis, MissouriAges 18 years+ - NCT04817956RecruitingPhase 2
Precision-medicine treatment for advanced cancer in Norway
This Phase 2 trial tries to match people with advanced cancer to targeted treatments based on their tumor’s genetic results. It may help if standard cancer treatments are no longer working or aren’t available, and if a “target” in the tumor suggests a therapy that could work.
ÅlesundAges 16 years+ - NCT04597294RecruitingPhase 3
Preventive pre-op HIPEC for advanced stomach cancer
This Phase 3 trial studies whether adding a heated chemotherapy procedure during surgery (HIPEC) before the main cancer treatment can lower the chance that stomach cancer returns in the belly. It is for people with advanced stomach cancer who are at higher risk of cancer coming back in the peritoneum (the lining of the abdomen).
Krakow, Lesser Poland VoivodshipAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,553 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.